Alessio Gasperetti,Richard T Carrick,Alexandros Protonotarios,Brittney Murray,Mikael Laredo,Iris van der Schaaf,Ronald H Lekanne,Petros Syrris,Douglas Cannie,Crystal Tichnell,Chiara Cappelletto,Marta Gigli,Kristen Medo,Ardan M Saguner,Firat Duru,Nisha A Gilotra,Stefan Zimmerman,Robyn Hylind,Dominic J Abrams,Neal K Lakdawala,Julia Cadrin-Tourigny,Mattia Targetti,Iacopo Olivotto,Maddalena Graziosi,Moniek Cox,Elena Biagini,Philippe Charron,Michela Casella,Claudio Tondo,Momina Yazdani,James S Ware,Sanjay K Prasad,Leonardo Calò,Eric D Smith,Adam S Helms,Sophie Hespe,Jodie Ingles,Harikrishna Tandri,Flavie Ader,Giovanni Peretto,Stacey Peters,Ari Horton,Jess Yao,Sven Dittmann,Eric Schulze-Bahr,Maria Qureshi,Katelyn Young,Eric D Carruth,Chris Haggerty,Victoria N Parikh,Matthew Taylor,Luisa Mestroni,Arthur Wilde,Gianfranco Sinagra,Marco Merlo,Estelle Gandjbakhch,J Peter van Tintelen,Anneline S J M Te Riele,Perry M Elliott,Hugh Calkins,Cynthia A James

Abstract:Background and aims: Pathogenic variants in the desmoplakin (DSP) gene are associated with the development of a distinct arrhythmogenic cardiomyopathy phenotype not fully captured by either dilated cardiomyopathy (DCM), non-dilated left ventricular cardiomyopathy (NDLVC), or arrhythmogenic right ventricular cardiomyopathy (ARVC). Prior studies have described baseline DSP cardiomyopathy genetic, inflammatory, and structural characteristics. However, cohort sizes have limited full clinical characterization and identification of clinical and demographic predictors of sustained ventricular arrhythmias (VAs), heart failure (HF) hospitalizations, and transplant/death. In particular, the relevance of acute myocarditis-like episodes for subsequent disease course is largely unknown. Methods: All patients with pathogenic/likely pathogenic (P/LP) DSP variants in the worldwide DSP-ERADOS Network (26 academic institutions across nine countries) were included. The primary outcomes were the development of sustained VA and HF hospitalizations during follow-up. Fine-Gray regressions were used to test association between clinical and instrumental parameters and the development of outcomes. Results: Eight hundred patients [40.3 ± 17.5 years, 47.5% probands, left ventricular ejection fraction (LVEF) 49.5 ± 13.9%] were included. Over 3.7 [1.4-7.1] years, 139 (17.4%, 3.9%/year) and 72 (9.0%, 1.8%/year) patients experienced sustained VA and HF episodes, respectively. A total of 32.5% of individuals did not fulfil diagnostic criteria for ARVC, DCM, or NDLVC; their VA incidence was 0.5%/year. In multivariable regression, risk features associated with the development of VA were female sex [adjusted hazard ratio (aHR) 1.547; P = .025], prior non-sustained ventricular tachycardia (aHR 1.721; P = .009), prior sustained VA (aHR 1.923; P = .006), and LVEF ≤ 50% (aHR: 1.645; P = .032), while for HF, they were the presence of T-wave inversion in 3+ electrocardiogram leads (aHR 2.036, P = .007) and LVEF ≤ 50% (aHR 3.879; P < .001). Additionally, 70 (8.8%) patients experienced a myocardial injury episode at presentation or during follow-up. These episodes were associated with an increased risk of VA and HF thereafter (HR 2.394; P < .001, and HR 5.064, P < .001, respectively). Conclusions: Patients with P/LP DSP variants experience high rates of sustained VA and HF hospitalizations. These patients demonstrate a distinct clinical phenotype (DSP cardiomyopathy), whose most prominent risk features associated with adverse clinical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wave inversion in 3+ leads on electrocardiogram, LVEF ≤ 50%, and myocardial injury events.

Desmoplakin Cardiomyopathy in Pediatric Patients: A Distinct, Underrecognized Cohort of Arrhythmogenic Cardiomyopathy

Next-generation Sequencing Identified Novel Desmoplakin Frame-Shift Variant in Patients with Arrhythmogenic Cardiomyopathy

Desmoplakin cardiomyopathy: case report

Clinical features and outcomes in carriers of pathogenic desmoplakin variants

DSP-Related Cardiomyopathy as a Distinct Clinical Entity? Emerging Evidence from an Italian Cohort

Abstract 58: Modeling Pathogenesis in Familial Hypertrophic Cardiomyopathy Using Patient-Specific Induced Pluripotent Stem Cells

A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers

Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis

LV-predominant arrhythmogenic cardiomyopathy related to pathogenic DSP-variant

Ventricular Tachycardia Ablation in Patients With Desmoplakin Cardiomyopathy

A novel desmoplakin mutation causes dilated cardiomyopathy with palmoplantar keratoderma as an early clinical sign

Malignant Arrhythmia with Variants of Desmocollin-2 and Desmoplakin Genes.

Clinical Feature and Profile of Desmoplakin Gene Mutation in Arrhythmogenic Right Ventricular Cardiomyopathy

Misdiagnosed myocarditis in arrhythmogenic cardiomyopathy induced by a homozygous variant of DSG2: a case report

Long-Term Arrhythmic Follow-Up and Risk Stratification of Patients With Desmoplakin-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

PANoptosis is a prominent feature of desmoplakin cardiomyopathy

Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry

Susceptibility to innate immune activation in genetically mediated myocarditis

Case report: Additional variants induced sudden cardiac death among pediatric ACM with DSG2 homozygous mutant genotype: a report of three cases

Desmoplakin mutations in cardiac fibroblasts cause TGFβ1-mediated pathological fibrogenesis in desmoplakin cardiomyopathy via beclin-1 regulation

Diagnosis and management of arrhythmogenic cardiomyopathy: a case report